Euro
USD
British Pound
NULL
Product Description
SLC22A2 Antibody | 60-152 | ProSci
Host: Rabbit
Reactivity: Human
Homology: N/A
Immunogen: This SLC22A2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 514-541 amino acids from the C-terminal region of human SLC22A2.
Research Area: Signal Transduction
Tested Application: WB
Application: For WB starting dilution is: 1:1000
Specificiy: N/A
Positive Control 1: N/A
Positive Control 2: N/A
Positive Control 3: N/A
Positive Control 4: N/A
Positive Control 5: N/A
Positive Control 6: N/A
Molecular Weight: 63 kDa
Validation: N/A
Isoform: N/A
Purification: This antibody is purified through a protein A column, followed by peptide affinity purification.
Clonality: Polyclonal
Clone: N/A
Isotype: Rabbit Ig
Conjugate: Unconjugated
Physical State: Liquid
Buffer: Supplied in PBS with 0.09% (W/V) sodium azide.
Concentration: batch dependent
Storage Condition: Store at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Alternate Name: Solute carrier family 22 member 2, Organic cation transporter 2, hOCT2, SLC22A2, OCT2
User Note: Optimal dilutions for each application to be determined by the researcher.
BACKGROUND: SLC22A2 mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine) , serotonin, choline, famotidine, ranitidine, histamin, creatinine, amantadine, memantine, acriflavine, 4-[4- (dimethylamino) -styryl]-N-methylpyridinium ASP, amiloride, metformin, N-1-methylnicotinamide (NMN) , tetraethylammonium (TEA) , 1-methyl-4-phenylpyridinium (MPP) , cimetidine, cisplatin and oxaliplatin. Cisplatin may develop a nephrotoxic action. Transport of creatinine is inhibited by fluoroquinolones such as DX-619 and LVFX. This transporter is a major determinant of the anticancer activity of oxaliplatin and may contribute to antitumor specificity.
